Detalles de la búsqueda
1.
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).
Oncologist
; 28(8): 722-729, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37284847
2.
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Support Care Cancer
; 32(1): 36, 2023 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38105286
3.
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
Support Care Cancer
; 31(12): 654, 2023 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37878086
4.
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
Oncologist
; 26(4): 325-331, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33289268
5.
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Future Oncol
; 17(23): 3027-3035, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33878896
6.
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.
Support Care Cancer
; 29(8): 4269-4275, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33409724
7.
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
Support Care Cancer
; 29(7): 3439-3459, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33442782
8.
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.
J Natl Compr Canc Netw
; 18(6): 676-681, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32502985
9.
Nausea and Vomiting in Advanced Cancer.
Curr Treat Options Oncol
; 21(2): 14, 2020 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32025954
10.
Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies.
Future Oncol
; 16(24): 1863-1872, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32543309
11.
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
N Engl J Med
; 375(2): 134-42, 2016 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-27410922
12.
HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
Future Oncol
; 15(3): 241-255, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30304952
13.
Managing Nausea and Vomiting in Patients With Cancer: What Works.
Oncology (Williston Park)
; 32(3): 121-5, 131, 136, 2018 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29548068
14.
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
Support Care Cancer
; 26(8): 2519-2549, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29796708
15.
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.
Support Care Cancer
; 30(2): 1015-1018, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34613472
16.
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Support Care Cancer
; 25(1): 303-308, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815710
17.
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
Support Care Cancer
; 25(1): 277-288, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27443154
18.
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Biochim Biophys Acta
; 1848(10 Pt B): 2738-46, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25838122
19.
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
Support Care Cancer
; 24(5): 2381-2392, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26768437
20.
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Lancet Oncol
; 16(9): 1071-1078, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272768